CASI Pharmaceuticals Announces Pricing Of $32,500,000 Public Offering Of Common StockPRNewsWire • 03/24/21
CASI Pharmaceuticals Partner, BioInvent, To Host Key Opinion Leader Call On BI-1206 For Relapsed Or Refractory Non-Hodgkin's LymphomaPRNewsWire • 01/21/21
CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy DesignationPRNewsWire • 12/23/20
CASI Pharmaceuticals Announces Partner Juventas Completes $65 Million Financing And Initiates Registration Study For CNCT19 (CD19 CAR-T)PRNewsWire • 11/19/20
CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/10/20
CASI Pharmaceuticals To Report Third Quarter 2020 Financial Results And Host Conference Call November 9, 2020PRNewsWire • 11/05/20
Week In Review: CStone Out-Licenses Ex-China Rights To 2 Immunotherapies In $1.3 Billion DealSeeking Alpha • 11/01/20
BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China regionPRNewsWire • 10/27/20
CASI Pharmaceuticals Announces Poster Presentation At The 2020 AABB Virtual Annual MeetingPRNewsWire • 10/02/20
CASI Pharmaceuticals To Report Second Quarter 2020 Financial Results And Host Conference Call August 10, 2020PRNewsWire • 08/03/20
CASI Pharmaceuticals Announces Pricing Of $38,000,000 Public Offering Of Common StockPRNewsWire • 07/22/20
CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody ProgramPRNewsWire • 06/08/20